300244 迪安诊断
2023/12 -
人民幣(K¥)

变动
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
营业总收入13,408,320-33.89%13,082,61310,649,1628,453,2076,966,857
减:营业总成本12,243,282-26.26%11,084,4098,862,6487,613,1826,224,057
    其中:营业成本9,213,383-27.71%8,076,9496,578,7065,735,3994,595,100
               财务费用220,608-26.03%217,479195,875208,715171,051
               资产减值损失(16,738)-97.32%(272,189)(475,247)(176,750)(107,247)
公允价值变动收益(727)-98.71%83,354(2,586)14,839(482)
投资收益(17,596)-136.07%55,33873,14899,54772,173
    其中:对联营企业和合营企业的投资收益(6,722)-125.12%39,78520,78338,26127,783
营业利润842,183-70.16%1,837,9351,320,311774,571721,398
利润总额798,326-68.61%1,790,9971,317,395771,175734,074
减:所得税费用216,735-68.18%307,396247,461195,607145,612
净利润581,591-68.77%1,483,6011,069,934575,568588,462
减:非控股权益274,130-35.99%320,717267,002228,286199,853
股东净利润307,461-78.56%1,162,884802,933347,282388,608

市场价值指针
每股收益 (元) *0.492-78.64%1.8741.2940.5600.710
每股派息 (元) *0.060-70.00%0.1350.1300.1280.025
每股净资产 (元) *12.0691.59%9.4167.5726.4215.925
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容